<DOC>
	<DOCNO>NCT02815410</DOCNO>
	<brief_summary>Prospective , open-labeled , multicenter cohort trial validation role levetiracetam sensitizer temozolomide treatment newly diagnose glioblastoma patient .</brief_summary>
	<brief_title>Validation Role Levetiracetam Newly Diagnosed GBM Patients</brief_title>
	<detailed_description>I . Objectives &lt; Primary Endpoint &gt; 6 month progression-free survival ( 6m-PFS ) &lt; Secondary Endpoint &gt; 1 . Overall survival 2 . Safety ( adverse event ) 3 . Quality life use EORTC module , 4 . Cognitive function use NOPT module institution &lt; Explorative Endpoint &gt; Genetic biomarker predict prognosis 1 . Methylation status MGMT promoter 2 . IDH mutation 3 . TERT mutation / ATRX status II . Hypothesis 1.Proof concept - With use levetiracetam , improve survival chemoradiotherapy temozolomide compare group without use levetiracetam . ( superiority ) 2 . Safety - It tolerable concept . 3 . Genetic biomarker - Methylation status MGMT , IDH1 mutation , TERT mutation , ATRX status prove valid molecular marker prognostic significance newly diagnose glioblastoma treat combination levetiracetam . III . Study Design/Clinical Plan 1 . Group I ( prospective ) - Patients group newly diagnose glioblastoma patient suppose treated concurrent chemoradiotherapy ( CCRT ) adjuvant chemotherapy temozolomide ( TMZ ) . Patients Group I give levetiracetam ( LEV ) begin treatment till adjuvant chemotherapy TMZ . 2 . Group II ( historical group ; use data base KSNO multicenter study group ) IV . Treatment 1 . Levetiracetam : start 250mg bid increase 500mg bid perioperative period . During 2 day peri-operation , administer intravenous form mixed 150ml normal saline . After immediate postoperative period , 500~1500mg bid administer per oral form accord patient 's clinical condition . During period adjuvant chemotherapy temozolomide , dose less 500mg administered unless serious side effect levetiracetam . 2 . Temozolomide base standard treatment : CCRT temozolomide follow 6cycles adjuvant temozolomide RT daily temozolomide ( 75 mg/m2/day , 7 days/week ) first last day radiotherapy ) , follow six cycle adjuvant temozolomide ( 150 200 mg/m2 5 day 28-day cycle ) . V. Evaluation MR scan perform first adjuvant treatment cycle every 3 month first year , every 4 month second year . Radiographic response determine comparison tumor measurement obtain pretreatment baseline measurement reference categorize four group use new criterion propose Response Assessment Neuro-Oncology ( RANO ) work group . VI . Statistical Plans Total sample size : 73 The size sample consider assessment PFS . The number event statistical power calculate assumption exponential distribution 7 month median PFS control group 12 month median PFS treatment group . The expected sample size provide 80 % test power perceive 1.7 hazard ration 0.05 type I error comparative analysis PFS time 12 month register period ( equal entry pattern ) 6 month follow period . Basis assumption , expect 73 patient need treatment group , 74 patient control group .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1 . Newly diagnose histologically proven supratentorial glioblastoma ( World Health Organization [ WHO ] Grade IV ) . The histological diagnosis must obtain neurosurgical resection biopsy tumor include open biopsy stereotactic biopsy . 2 . Age 20 76 year 3 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 4 . Meets 1 follow RPA classification : 41 . Class III ( Age &lt; 50 year ECOG PS 0 ) 42 . Class IV ( meet one follow criterion : ) Age &lt; 50 year ECOG PS 1 b ) Age ≥50 year , underwent prior partial total tumor resection , MMSE ≥27 ) 43 . Class V ( meet one follow criterion : ) Age ≥50 year underwent prior partial total tumor resection , MMSE &lt; 27 b ) Age ≥50 year underwent prior tumor biopsy ) 5 . Adequate hematologic , renal , hepatic function : ANC &gt; 1,500/uL Platelet &gt; 100,000/uL Serum creatinine &lt; 1.7mg/dL Bilirubin level &lt; 2.0 mg/dL AST/ALT &lt; 2.5 x upper limit normal range institution 6 . Written inform consent 1 . Prior chemotherapy within last 5 year 2 . Prior radiotherapy head neck area 3 . Receiving concurrent investigational agent receive investigational agent within 30 day prior randomization 4 . Planned surgery disease ( e.g . dental extraction ) 5 . History malignancy . Subjects curatively treated cervical carcinoma situ basal cell carcinoma skin , subject free malignancy 5 year eligible study 6 . Pregnant lactate woman 7 . Subject disagree follow acceptable method contraception 8 . Concurrent illness include unstable heart disease despite appropriate treatment , history myocardial infarction within 6 month , serious neurological psychological disease , uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Survival outcome</keyword>
</DOC>